Non-Small Cell Lung Carcinoma (NSCLC) Market
Market Insights on Non-Small Cell Lung Carcinoma (NSCLC) covering sales outlook, demand forecast & up-to-date key trends
Non-Small Cell Lung Carcinoma (NSCLC) Market by Type, Treatment, End User & Region – Forecast 2023–2033
Non-Small Cell Lung Carcinoma (NSCLC) Market Snapshot (2023-2033)
The global non-small cell lung carcinoma (NSCLC) market is expected to garner a market value of US$ 8.25 Billion in 2023 and is expected to accumulate a market value of US$ 21.40 Billion by registering a CAGR of 10% in the forecast period 2023-2033. Growth of the non-small cell lung carcinoma (NSCLC) market can be attributed to rising prevalence of NSCLC across the globe due to increasing air pollution and smoking habits amongst the people. The market for non-small cell lung carcinoma (NSCLC) registered a CAGR of 7.3% in the historical period 2017-2022.
The presence of a strong pipeline for non-small cell lung carcinoma is projected to propel the growth over the coming years. For instance, “fruquintinib (HMPL-013)”, a drug developed to treat advanced non-small cell lung carcinoma is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, development of such advanced treatments is expected to drive the market during the forecast period.
|
Report Attribute |
Details |
|
Estimated Base Year Value (2021) |
US$ 7.5 Billion |
|
Expected Market Value (2023) |
US$ 8.25 Billion |
|
Anticipated Forecast Value (2033) |
US$ 21.4 Billion |
|
Projected Growth Rate (2023-2033) |
10% CAGR |
Let us know your requirement to get
100% FREE customization
2017-2022 Non-small Cell Lung Carcinoma (NSCLC) Market Demand Analysis vs. Forecast 2023-2033
According to market research and competitive intelligence provider Future Market Insights- the market for non-small cell lung carcinoma (NSCLC) reflected a value of 7.3% during the historical period, 2018- 2022.
Several market players halted their clinical trials due to a financial crisis in the year. For instance, according to clinicaltrials.gov in July 2021, it was observed that more than 200 interventional studies were halted from March to April 2020 due to the emergence of COVID-19. Additionally, fluctuation in the market is mainly due to the disruption in the supply chain of raw materials and end products.
Moreover, according to an article published in September 2020 titled "The impact of the COVID-19 pandemic on lung cancer patients," at the Fifth Affiliated Hospital of Sun Yat-sen University, around 95 patients out of 161 had delayed their return visit in April 2020, and 47 cases were finally designated as having delayed admission during the pandemic and having to discontinue or delay their regular anticancer treatments. Thus, the market for non-small cell lung carcinoma (NSCLC) is expected to register a CAGR of 10% in the forecast period 2023-2033.
Which are Some Prominent Drivers of Non-Small cell Lung Carcinoma (NSCLC) Market?
Smoking and tobacco consumption increasing number of patients suffering from non-small cell lung carcinoma
The American Cancer Society estimates that lung cancer is the one of the highest death-causing diseases across the world. Covid-19 significantly affected the non-small cell lung cancer-related clinical trials across the world. However, cancer care and maintaining high standards of diagnosis and treatment have been the major priorities of the national healthcare bodies and international healthcare systems worldwide.
The growing number of patients suffering from non-small cell lung cancer across the world is one of the key drivers of the growth of the market. This is majorly due to the increasing number of people with unhealthy habits such as smoking, tobacco & alcohol consumption, high dose of supplements, and sedentary lifestyle across the world. Additionally, increasing pollution level in the air is also one of the major factors contributing to the increase in the number of patients.
Approvals of Medication for Lung Carcinoma Propelling Market Growth
As per the statistics provided by the World Health Organization (WHO) updates from February 2022, 2.2 Billion patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of the share of all lung cancer patients. Thus, the availability of a large patient base and a further increasing number of non-small cell lung carcinoma patients resulted in the high demand for treating the patients.
Recent approvals of new drugs are expected to accelerate the market growth during the forecast period. For instance, In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in the United States. Additionally, in October 2021, Ventana Medical Systems, Inc. received United States FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Non-Small cell Lung Carcinoma (NSCLC) Market?
Longer Duration for approval of Medication hampering Growth of Market
The expensive nature of research and development of medication to treat patients is derailing the progress of the market. In addition, the financial burden added by the COVID-19 pandemic is playing a key role in hindering the growth of the market. Furthermore, the time taken for approval of drugs along with certain medications not being approved in spite of being in the clinical trial phase for a longer duration are hampering the overall growth of the non-small cell lung carcinoma market.
Region-Wise Insights
Research and Development Activities Favoring Growth of Non-Small Cell Lung Carcinoma Market in North America?
Launch of new drugs creating Favorable treatment for non-small cell lung carcinoma in North America
North America is expected to maintain its dominance during the forecast period and is one of the most lucrative regions for the NSCLC market. This is due to the presence of a strong pipeline and research activities undertaken by various industry players and academic institutions.
Thus, North America is expected to account for the largest share of all the regions in 2023. This is attributed to the entry of newer drugs, high investment by players, acceptance of costly drugs, and increased government funding for research and development activities. Owing to the aforementioned reasons, North America is expected to possess 40% market share for non-cell lung carcinoma market in 2023.
Large Patient Pool Creating Lucrative Opportunities for Non-Small Cell Lung Carcinoma Market in Asia Pacific?
Less stringent regulator framework opening doors for medication development in Asia Pacific
Asia Pacific is expected to be the second largest contributor in 2023 for non-small lung cell carcinoma market. This is owing to the presence of less stringent regulatory procedures for approval and a large patient pool. Japan and China are expected to contribute highest to the Asia Pacific region due to the availability of advanced drugs, developed economy, and a large patient pool.
Pricing pressure by the governments of European countries is likely to affect the market negatively during the forecast period. For instance, in October 2016, the National Institute for Health and Care Excellence (NICE) disapproved funding for Opdivo, as it did not meet the required cost-to-benefit ratio. Thus, Asia Pacific is expected to possess 35% market share for non-small cell lung carcinoma market.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Market Competition
Key players in the market are non-small cell lung carcinoma market AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline plc, Novartis, Pfizer Inc, Roche Holding AG, Sun Pharmaceutical Industries Ltd.
- In June 2021, AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.
- Pfizer, another key player in the non-small cell lung carcinoma is focusing on investing in research and development in manufacturing medications depending on the ailment. Thus, the company plans to examine its medication through clinical trial for receiving approval.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 8.25 Billion |
|
Market Value in 2033 |
US$ 21.4 Billion |
|
Growth Rate |
CAGR of 10% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2017-2022 |
|
Forecast Period |
2023-2033 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Non-Small cell Lung Carcinoma (NSCLC) Industry Survey
Type:
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Large Cell Neruoendocrine Tumors
Treatment:
- Chemotherapy
- Targeted Therapy
- Bevacizumab (Avastin)
- Nectiumumbab (Portrazza)
- Ramucirumab (Cyramza)
- Immunotherapy
- Nivolumab (Opdivo)
- Atezolizumab (Tecentrig)
- Others
End User:
- Hospitals
- Homecare
- Specialty Clinics
- Others
Region:
- North America
- Latin America
- Europe
- South Asia & Pacific
- East Asia
- Middle East & Africa
Frequently Asked Questions
From 2018-2022, the non-small cell lung carcinoma (NSCLC) market grew at a CAGR of 7.3%
The global non-small cell lung carcinoma (NSCLC) market is expected to grow with a 10% CAGR during 2023-2033.
As of 2033, the non-small cell lung carcinoma (NSCLC) market is expected to reach US$ 21.40 Billion
North America is expected to possess 40% market share for non-small cell lung carcinoma (NSCLC) market in North America.
Asia Pacific is expected to possess 35% market share for non-small cell lung carcinoma market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Type, 2018-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type, 2023-2033
5.3.1. Adenocarcinoma
5.3.2. Squamous Cell Carcinoma
5.3.3. Large Cell Carcinoma
5.3.4. Large Cell Neuroendocrine Tumors
5.4. Y-o-Y Growth Trend Analysis By Type, 2018-2022
5.5. Absolute $ Opportunity Analysis By Type, 2023-2033
6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2018-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2023-2033
6.3.1. Chemotherapy
6.3.2. Targeted Therapy
6.3.2.1. Bevacizumab (Avastin)
6.3.2.2. Necitumumab (Portrazza)
6.3.2.3. Ramucirumab (Cyramza)
6.3.3. Immunotherapy
6.3.3.1. Nivolumab (Opdivo)
6.3.3.2. Atezolizumab (Tecentriq)
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018-2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023-2033
7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End User , 2018-2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User , 2023-2033
7.3.1. Hospitals
7.3.2. Homecare
7.3.3. Specialty Clinics
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End User , 2018-2022
7.5. Absolute $ Opportunity Analysis By End User , 2023-2033
8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia & Pacific
8.3.5. East Asia
8.3.6. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Type
9.2.3. By Treatment
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Treatment
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. By Treatment
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Treatment
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Type
11.2.3. By Treatment
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Treatment
11.3.4. By End User
11.4. Key Takeaways
12. South Asia & Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Australia
12.2.1.6. New Zealand
12.2.1.7. Rest of South Asia & Pacific
12.2.2. By Type
12.2.3. By Treatment
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Treatment
12.3.4. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Type
13.2.3. By Treatment
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Treatment
13.3.4. By End User
13.4. Key Takeaways
14. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Type
14.2.3. By Treatment
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Treatment
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Type
15.1.2.2. By Treatment
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Type
15.2.2.2. By Treatment
15.2.2.3. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Type
15.3.2.2. By Treatment
15.3.2.3. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Type
15.4.2.2. By Treatment
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Type
15.5.2.2. By Treatment
15.5.2.3. By End User
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Type
15.6.2.2. By Treatment
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Type
15.7.2.2. By Treatment
15.7.2.3. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Type
15.8.2.2. By Treatment
15.8.2.3. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Type
15.9.2.2. By Treatment
15.9.2.3. By End User
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Type
15.10.2.2. By Treatment
15.10.2.3. By End User
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Type
15.11.2.2. By Treatment
15.11.2.3. By End User
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Type
15.12.2.2. By Treatment
15.12.2.3. By End User
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Type
15.13.2.2. By Treatment
15.13.2.3. By End User
15.14. Australia
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Type
15.14.2.2. By Treatment
15.14.2.3. By End User
15.15. New Zealand
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Type
15.15.2.2. By Treatment
15.15.2.3. By End User
15.16. China
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Type
15.16.2.2. By Treatment
15.16.2.3. By End User
15.17. Japan
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Type
15.17.2.2. By Treatment
15.17.2.3. By End User
15.18. South Korea
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Type
15.18.2.2. By Treatment
15.18.2.3. By End User
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Type
15.19.2.2. By Treatment
15.19.2.3. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Type
15.20.2.2. By Treatment
15.20.2.3. By End User
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Type
15.21.2.2. By Treatment
15.21.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Type
16.3.3. By Treatment
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Pfizer Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. AstraZeneca plc
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. F. Hoffmann-La Roche Ltd.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Eli Lilly and Company
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Boehringer Ingelheim GMBH
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Novartis AG
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Bristol-Myers Squibb Company
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Merck & Co., Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Celgene Corp.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Sun Pharmaceutical Industries Ltd.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033
Table 2: Global Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 3: Global Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 4: Global Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 5: North America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 6: North America Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 7: North America Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 8: North America Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 10: Latin America Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 11: Latin America Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 12: Latin America Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 14: Europe Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 15: Europe Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 16: Europe Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 17: South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 18: South Asia & Pacific Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 19: South Asia & Pacific Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 20: South Asia & Pacific Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 21: East Asia Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 22: East Asia Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 23: East Asia Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 24: East Asia Market Value (US$ Mn) Forecast by End User , 2018-2033
Table 25: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 26: MEA Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 27: MEA Market Value (US$ Mn) Forecast by Treatment, 2018-2033
Table 28: MEA Market Value (US$ Mn) Forecast by End User , 2018-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Type, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Treatment, 2023-2033
Figure 3: Global Market Value (US$ Mn) by End User , 2023-2033
Figure 4: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2018-2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 8: Global Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 11: Global Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 14: Global Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 17: Global Market Attractiveness by Type, 2023-2033
Figure 18: Global Market Attractiveness by Treatment, 2023-2033
Figure 19: Global Market Attractiveness by End User , 2023-2033
Figure 20: Global Market Attractiveness by Region, 2023-2033
Figure 21: North America Market Value (US$ Mn) by Type, 2023-2033
Figure 22: North America Market Value (US$ Mn) by Treatment, 2023-2033
Figure 23: North America Market Value (US$ Mn) by End User , 2023-2033
Figure 24: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 28: North America Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 31: North America Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 34: North America Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 37: North America Market Attractiveness by Type, 2023-2033
Figure 38: North America Market Attractiveness by Treatment, 2023-2033
Figure 39: North America Market Attractiveness by End User , 2023-2033
Figure 40: North America Market Attractiveness by Country, 2023-2033
Figure 41: Latin America Market Value (US$ Mn) by Type, 2023-2033
Figure 42: Latin America Market Value (US$ Mn) by Treatment, 2023-2033
Figure 43: Latin America Market Value (US$ Mn) by End User , 2023-2033
Figure 44: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 48: Latin America Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 51: Latin America Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 54: Latin America Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 57: Latin America Market Attractiveness by Type, 2023-2033
Figure 58: Latin America Market Attractiveness by Treatment, 2023-2033
Figure 59: Latin America Market Attractiveness by End User , 2023-2033
Figure 60: Latin America Market Attractiveness by Country, 2023-2033
Figure 61: Europe Market Value (US$ Mn) by Type, 2023-2033
Figure 62: Europe Market Value (US$ Mn) by Treatment, 2023-2033
Figure 63: Europe Market Value (US$ Mn) by End User , 2023-2033
Figure 64: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 68: Europe Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 71: Europe Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 74: Europe Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 77: Europe Market Attractiveness by Type, 2023-2033
Figure 78: Europe Market Attractiveness by Treatment, 2023-2033
Figure 79: Europe Market Attractiveness by End User , 2023-2033
Figure 80: Europe Market Attractiveness by Country, 2023-2033
Figure 81: South Asia & Pacific Market Value (US$ Mn) by Type, 2023-2033
Figure 82: South Asia & Pacific Market Value (US$ Mn) by Treatment, 2023-2033
Figure 83: South Asia & Pacific Market Value (US$ Mn) by End User , 2023-2033
Figure 84: South Asia & Pacific Market Value (US$ Mn) by Country, 2023-2033
Figure 85: South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 86: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 87: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 88: South Asia & Pacific Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 89: South Asia & Pacific Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 90: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 91: South Asia & Pacific Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 92: South Asia & Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 93: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 94: South Asia & Pacific Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 95: South Asia & Pacific Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 96: South Asia & Pacific Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 97: South Asia & Pacific Market Attractiveness by Type, 2023-2033
Figure 98: South Asia & Pacific Market Attractiveness by Treatment, 2023-2033
Figure 99: South Asia & Pacific Market Attractiveness by End User , 2023-2033
Figure 100: South Asia & Pacific Market Attractiveness by Country, 2023-2033
Figure 101: East Asia Market Value (US$ Mn) by Type, 2023-2033
Figure 102: East Asia Market Value (US$ Mn) by Treatment, 2023-2033
Figure 103: East Asia Market Value (US$ Mn) by End User , 2023-2033
Figure 104: East Asia Market Value (US$ Mn) by Country, 2023-2033
Figure 105: East Asia Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 108: East Asia Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 111: East Asia Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 114: East Asia Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 117: East Asia Market Attractiveness by Type, 2023-2033
Figure 118: East Asia Market Attractiveness by Treatment, 2023-2033
Figure 119: East Asia Market Attractiveness by End User , 2023-2033
Figure 120: East Asia Market Attractiveness by Country, 2023-2033
Figure 121: MEA Market Value (US$ Mn) by Type, 2023-2033
Figure 122: MEA Market Value (US$ Mn) by Treatment, 2023-2033
Figure 123: MEA Market Value (US$ Mn) by End User , 2023-2033
Figure 124: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 125: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 128: MEA Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 129: MEA Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 130: MEA Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 131: MEA Market Value (US$ Mn) Analysis by Treatment, 2018-2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023-2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033
Figure 134: MEA Market Value (US$ Mn) Analysis by End User , 2018-2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by End User , 2023-2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by End User , 2023-2033
Figure 137: MEA Market Attractiveness by Type, 2023-2033
Figure 138: MEA Market Attractiveness by Treatment, 2023-2033
Figure 139: MEA Market Attractiveness by End User , 2023-2033
Figure 140: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
